Stay updated on ARRY-382 Combo With Pembrolizumab in Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the ARRY-382 Combo With Pembrolizumab in Solid Tumors Clinical Trial page.

Latest updates to the ARRY-382 Combo With Pembrolizumab in Solid Tumors Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedRevision: v3.3.2 was added and v3.3.1 was removed; no changes to the study details page are visible.SummaryDifference0.0%

- Check21 days agoChange DetectedThe Publications section now states that publications are automatically filled from PubMed, and the Revision tag shows v3.3.1 (previously v3.2.0). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check29 days agoChange DetectedThe government funding status notice warning about potential data that may be out of date has been removed from the page.SummaryDifference0.3%

- Check43 days agoChange DetectedAdded a comprehensive Results section with primary and secondary outcomes and safety data for NCT02880371. The section includes ORR, DOR, PFS, OS, irRR, and adverse events.SummaryDifference0.3%

- Check71 days agoChange DetectedUpgrade to v3.2.0 with a government operating-status notice and links to status pages; removes the previous v3.1.0 reference.SummaryDifference2%

- Check79 days agoChange DetectedPage revision updated from v3.0.2 to v3.1.0, indicating a version bump with no other substantive content changes.SummaryDifference0.0%

Stay in the know with updates to ARRY-382 Combo With Pembrolizumab in Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ARRY-382 Combo With Pembrolizumab in Solid Tumors Clinical Trial page.